Update
$Ocugen(OCGN.US$ Ocugen Announces Dosing Completion of Subjects With Geographic Atrophy in Cohort 2 of Phase 1/2 Armada Clinical Trial of Ocu410—a Modifier Gene Therapy
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
